AMPH vs INCY: fair value comparison
Amphastar Pharmaceuticals, Inc. and Incyte Corporation · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our ranking by discount to fair value. INCY carries the stronger quality grade.
| AMPH | INCY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.87 | $112.79 |
| 12-month range | $16.87–$29.40 | $90.18–$129.93 |
| Rank by discount to fair value | #27 of 108 Healthcare | #23 of 108 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · INCY fair value analysis